Illumina’s Deal to Buy Cancer-Test Developer Is Blocked by EU
The bloc’s antitrust regulator said Tuesday the purchase would stifle innovation and reduce choice in an emerging market for early cancer-detection blood tests. The decision could force Illumina, a maker of gene-sequencing machines, to shed Grail just over a year after scooping it up. The antitrust regulator said Illumina didn’t offer sufficient remedies to address its concerns about the deal, and that it would issue a separate decision ordering Illumina and Grail to dissolve their transaction.
“It is vital to…